The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis

Brain, Behavior, and Immunity

Volumn 35, Issue , 2014, Pages 96-101

  Iaffaldano, Pietro ^a   Ruggieri, Maddalena ^a   Viterbo, Rosa Gemma ^a   Mastrapasqua, Mariangela ^a   Trojano, Maria ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Cognition; Multiple sclerosis; Neuropsychology; Psychoneuroimmunology

Indexed keywords

BETA INTERFERON; GLATIRAMER; NATALIZUMAB; OSTEOPONTIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84888873502     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2013.08.009     Document Type: Article

References (32)

1. Amato M.P., Portaccio E., Goretti B., Zipoli V., Ricchiuti L., et al. The Rao's brief repeatable battery and Stroop test: normative values with age, education and gender corrections in an Italian population. MultScler 2006, 12:787-793.
2. Börnsen L., Khademi M., Olsson T., Sørensen P.S., Sellebjerg F. Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. MultScler 2011, 17(1):32-42.
3. Braitch M., Nunan R., Niepel G., Edwards L.J., Constantinescu C.S. Increased Osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch. Neurol. 2008, 65(5):633-635.
4. Brown A., Islam T., Adams R., Nerle S., Kamara M., et al. Osteopontin enhances HIV replication and is increased in the brain and cerebrospinal fluid of HIV-infected individuals. J. Neurovirol. 2011, 17(4):382-392.
5. Brown A. Osteopontin: a key link between immunity, inflammation and the central nervous system. Transl. Neurosci. 2012, 3(3):288-293.
6. Burdo T.H., Wood M.R., Fox H.S. Osteopontin prevents monocyte recirculation and apoptosis. J. Leukoc. Biol. 2007, 81:1504-1511.
7. Burdo T.H., Ellis R.J., Fox H.S. Osteopontin is increased in HIV-associated dementia. J. Infect. Dis. 2008, 198(5):715-722.
8. Camp S.J., Stevenson V.L., Thompson A.J., Miller D.H., Borras C., et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis. A controlled study with MRI correlates. Brain 1999, 122:1341-1348.
9. Centonze D., Muzio L., Rossi S., Cavasinni F., De Chiara V., et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 2009, 29:3442-3452.
10. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., et al. The influence of the proinflammatory cytokine, Osteopontin, on autoimmune demyelinating disease. Science 2001, 294(5547):1731-1735.
11. Comabella M., Pericot I., Goertsches R., Nos C., Castillo M., et al. Plasma Osteopontin levels in multiple sclerosis. J. Neuroimmunol. 2005, 158:231-239.
12. Denhardt D.T., Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993, 7(15):1475-1482.
13. Glass J.D., Fedor H., Wesselingh S.L., McArthur J.C. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann. Neurol. 1995, 38:755-762.
14. Gunnarsson M., Malmeström C., Axelsson M., Sundström P., Dahle C., et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by Natalizumab. Ann. Neurol. 2010, 69(1):83-89.
15. Heesen C., Schulz K.H., Fiehler J., et al. Correlates of cognitive dysfunction in multiple sclerosis. Brain Behav. Immun. 2010, 24:1148-1155.
16. Hur E.M., Youssef S., Haws M.E., Zhang S.Y., Sobel R.A., Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhancedsurvival of activated T cells. Nat. Immunol. 2007, 8:74-83.
17. Iaffaldano P., Viterbo R.G., Paolicelli D., Lucchese G., Portaccio E., et al. Impact of Natalizumabon cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLoS ONE 2012, 7(4):e35843. 10.1371/journal.pone.0035843.
18. Khademi M., Bornsen L., Rafatnia F., et al. The effects of Natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur. J. Neurol. 2009, 16:528-536.
19. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinbrg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 1989, 46:1121-1123.
20. Mandolesi G., Grasselli G., Musumesi G., Centonze D. Cognitive deficits in experimental autoimmune encephalomyelitis: neuroinflammation and synaptic degeneration. Neurol. Sci. 2010, 31(Suppl. 2):S255-S259.
21. Mattioli F., Stampatori C., Bellomi F., Capra R. Natalizumab efficacy on cognitive impairment in MS. Neurol. Sci. 2011, 31(Suppl. 3):321-323.
22. Mellergard J., Edstrom M., Vrethem M., Erneurdh J., Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult. Scler. 2010, 16:208-217.
23. Murugaiyan G., Mittal A., Weiner H.L. Increased Osteopontin expression in dendritic cells amplifies IL-17 production by CD4 T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J. Immunol. 2008, 181:7480-7488.
24. Patti F., Amato M.P., Bastianello S., Caniatti L., Di Monte E., et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disable patients with relapsing remitting multiple sclerosis. Mult. Scler. 2010, 16(1):68-77.
25. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., et al. A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:899-910. for the AFFIRM Investigators.
26. Rao S.M., Leo G.J., Bernardin L., Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns and prediction. Neurology 1991, 41:685-691.
27. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:911-923. for the SENTINEL Investigators.
28. Steinman L. A molecular trio in relapse and remission in multiple sclerosis. NatRevImmunol. 2009, 9(6):440-447.
29. Viterbo R.G., Iaffaldano P., Trojano M. Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. J. Neurol. Sci. 2013, 330(1-2):56-60.
30. Vogt M., Lopatinskaya L., Smits M., Polman C.H., Nagelkerken L. Elevated Osteopontin levels in active relapsing-remitting multiple sclerosis. Ann. Neurol. 2008, 53:819-822.
31. Vogt M., ten Kate J., Drent R.M.J., Polman C.H., Hupperts R. Increased Osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult. Scler. 2010, 16(4):443-449.
32. Yu X.Q., Fan J.M., Nikolic-Paterson D.J., Yang N., Mu W., Pichler R., et al. IL-1 up-regulates Osteopontin expression in experimental crescentic glomerulonephritis in the rat. Am. J. Pathol. 1999, 154(3):833-841.